Literature DB >> 30264920

Allergic contact dermatitis caused by medical devices for diabetes patients: A review.

Anne Herman1, Laurence de Montjoye1, Isabelle Tromme1, An Goossens2, Marie Baeck1.   

Abstract

Allergic contact dermatitis caused by medical devices for diabetes patients has been increasingly described in the literature in the last few years. This article reviews the cases of allergic contact dermatitis caused by insulin pumps and glucose sensors reported since the 1970s, the culprit allergen(s), the results of patch tests and/or chromatographic analysis, and preventive measures.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  acrylate; allergic contact dermatitis; continuous glucose monitoring; cyanoacrylate; diabetes; insulin pump; isobornyl acrylate; medical devices

Mesh：

Substances：

Year:  2018        PMID： 30264920     DOI： 10.1111/cod.13120

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN： 0105-1873            Impact factor:   6.600


  13 in total

1.  Cutaneous Reactions to Continuous Glucose Monitoring and Continuous Subcutaneous Insulin Infusion Devices in Type 1 Diabetes Mellitus.

Authors:  Rachel S Rigo; Laura E Levin; Donald V Belsito; Maria C Garzon; Rachelle Gandica; Kristen M Williams
Journal:  J Diabetes Sci Technol       Date:  2020-05-09

2.  Cutaneous Complications With Continuous or Flash Glucose Monitoring Use: Systematic Review of Trials and Observational Studies.

Authors:  Nurul A Mohd Asarani; Andrew N Reynolds; Sara E Boucher; Martin de Bock; Benjamin J Wheeler
Journal:  J Diabetes Sci Technol       Date:  2019-08-27

3.  High Frequency of Dermatological Complications in Children and Adolescents with Type 1 Diabetes: A Web-Based Survey.

Authors:  Fortunato Lombardo; Stefano Passanisi; Davide Tinti; Maria Francesca Messina; Giuseppina Salzano; Ivana Rabbone
Journal:  J Diabetes Sci Technol       Date:  2020-08-06

4.  The 'flash' adhesive study: a randomized crossover trial using an additional adhesive patch to prolong freestyle libre sensor life among youth with type 1 diabetes mellitus.

Authors:  Brooke L Marsters; Sara E Boucher; Barbara C Galland; Michel de Lange; Esko J Wiltshire; Martin I de Bock; Mona M Elbalshy; Paul A Tomlinson; Jenny Rayns; Karen E MacKenzie; Huan Chan; Benjamin J Wheeler
Journal:  Acta Diabetol       Date:  2020-06-09       Impact factor: 4.280

5.  In Response to the Letter to the Editor on Minimizing Adverse Skin Reactions to Wearable Continuous Glucose Monitoring Sensors.

Authors:  Martin Mowitz; Josefin Ulriksdotter; Magnus Bruze; Cecilia Svedman
Journal:  J Diabetes Sci Technol       Date:  2021-04-21

6.  Minimizing Adverse Skin Reactions to Wearable Continuous Glucose Monitoring Sensors in Patients With Diabetes.

Authors:  Alexander Seibold
Journal:  J Diabetes Sci Technol       Date:  2021-01-08

Review 7.  Insulin Pump Therapy for Patients With Type 2 Diabetes Mellitus: Evidence, Current Barriers, and New Technologies.

Authors:  Guido Freckmann; Sina Buck; Delia Waldenmaier; Bernhard Kulzer; Oliver Schnell; Ulrich Gelchsheimer; Ralph Ziegler; Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2020-06-01

Review 8.  Contact Allergy-Emerging Allergens and Public Health Impact.

Authors:  Wolfgang Uter; Thomas Werfel; Jean-Pierre Lepoittevin; Ian R White
Journal:  Int J Environ Res Public Health       Date:  2020-04-01       Impact factor: 3.390

9.  Improved well-being and decreased disease burden after 1-year use of flash glucose monitoring (FLARE-NL4).

Authors:  Marion Fokkert; Peter van Dijk; Mireille Edens; Eglantine Barents; Jeanine Mollema; Robbert Slingerland; Reinold Gans; Henk Bilo
Journal:  BMJ Open Diabetes Res Care       Date:  2019-12-09

Review 10.  Insulin Allergy to Detemir Followed by Rapid Onset of Diabetic Ketoacidosis: A Case Report and Literature Review.

Authors:  Chong Boon Teo; Pek Yan Tan; Shan Xian Lee; Joan Khoo; Jun Guan Tan; Su Fen Ang; Sze Hwa Tan; Tunn Lin Tay; Eberta Tan; Su Chi Lim; Bernhard O Boehm; Wann Jia Loh
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-08       Impact factor: 5.555
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.